Zhichuan Li1, Lanyan Fang2, Wenlei Jiang1, Myong-Jin Kim1, Liang Zhao1. 1. Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, 20993, USA. 2. Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, 20993, USA. Lanyan.Fang@fda.hhs.gov.
Abstract
PURPOSE OF REVIEW: This review summarizes the current FDA practice in developing risk- and evidence-based product-specific bioequivalence guidances for antiepileptic drugs (AEDs). RECENT FINDINGS: FDA's product-specific guidance (PSG) for AEDs takes into account the therapeutic index of each AED product. Several PSGs for AEDs recommend fully replicated studies and a reference-scaled average bioequivalence (RS-ABE) approach that permit the simultaneous equivalence comparison of the mean and within-subject variability of the test and reference products. The PSGs for AEDs published by FDA reflect the agency's current thinking on the bioequivalence studies and approval standards for generics of AEDs. Bioequivalence between brand and generic AED products demonstrated in controlled studies with epilepsy patients provides strong scientific support for the soundness of FDA bioequivalence standards.
PURPOSE OF REVIEW: This review summarizes the current FDA practice in developing risk- and evidence-based product-specific bioequivalence guidances for antiepileptic drugs (AEDs). RECENT FINDINGS: FDA's product-specific guidance (PSG) for AEDs takes into account the therapeutic index of each AED product. Several PSGs for AEDs recommend fully replicated studies and a reference-scaled average bioequivalence (RS-ABE) approach that permit the simultaneous equivalence comparison of the mean and within-subject variability of the test and reference products. The PSGs for AEDs published by FDA reflect the agency's current thinking on the bioequivalence studies and approval standards for generics of AEDs. Bioequivalence between brand and generic AED products demonstrated in controlled studies with epilepsypatients provides strong scientific support for the soundness of FDA bioequivalence standards.
Authors: Robert S Fisher; Walter van Emde Boas; Warren Blume; Christian Elger; Pierre Genton; Phillip Lee; Jerome Engel Journal: Epilepsia Date: 2005-04 Impact factor: 5.864
Authors: Barbara M Davit; Patrick E Nwakama; Gary J Buehler; Dale P Conner; Sam H Haidar; Devvrat T Patel; Yongsheng Yang; Lawrence X Yu; Janet Woodcock Journal: Ann Pharmacother Date: 2009-09-23 Impact factor: 3.154
Authors: Michael Privitera; Timothy Welty; Barry Gidal; Chad Carlson; John Pollard; Michel Berg Journal: Epilepsy Curr Date: 2014-07 Impact factor: 7.500
Authors: Tricia Y Ting; Wenlei Jiang; Robert Lionberger; Jessica Wong; Jace W Jones; Maureen A Kane; Allan Krumholz; Robert Temple; James E Polli Journal: Epilepsia Date: 2015-07-23 Impact factor: 5.864